COMMUNIQUÉS West-GlobeNewswire
-
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
21/01/2026 -
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
21/01/2026 -
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
21/01/2026 -
“Medical Travel Month” January 2026 Sponsored by Medical Travel & Digital Health News in SHSMD American Hospital Association’s Calendar of Health Observances
21/01/2026 -
Manhattan Wellness Joins Lumina Therapy Alliance, Expanding the Nation’s Premier In-Person Mental Health Network
21/01/2026 -
PerfectServe is Furthest in Vision and Highest in Execution in 2026 Gartner® Magic Quadrant™ for Clinical Communication and Collaboration
21/01/2026 -
Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products
21/01/2026 -
LiveWorld Announces Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap
21/01/2026 -
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
21/01/2026 -
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
21/01/2026 -
ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
21/01/2026 -
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
21/01/2026 -
NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts
21/01/2026 -
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
21/01/2026 -
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
21/01/2026 -
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
21/01/2026 -
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
21/01/2026 -
American Heart Association and Centre for Neuro Skills Deepen Relationship to Advance Stroke and Brain Injury Care
21/01/2026 -
Restore Brain Announces Expansion of Neuromodulation Footprint with New St. Louis Office, Bringing Advanced TMS and SPRAVATO Treatments to the Region
21/01/2026
Pages